Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory Muscle Strength Measures in Late-Onset Pompe Disease
2014-002158-38Phase 2Active
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of reveglucosidase alfa in Pompe disease (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Respiratory muscle strength (volitional vs non-volitional) at baseline. Started Jun 2015; status: active.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2014-002158-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002158-38.